96928 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
POLYMER MOLECULE, MONOMERIC STRUCTURE AND POLYMERIC STRUCTURE COMPRISING SAME
#2VACCINE COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN-SPECIFIC VACCINATION
#3MODIFIED POLYPEPTIDES AND USES THEREOF
#4Compositions and methods involving engineered P27
#5FUSION PROTEINS AND METHODS THEREOF
#6NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS
#7Quality Improving Agent for IPS Cells, Method of Producing IPS Cells, IPS Cells, and Composition for Producing IPS Cells
#8METHODS AND COMPOSITIONS RELATING TO CHIMERIC ANTIGEN RECEPTORS
#9Inhibitors of cyclin-dependent kinases
#10COMPOSITIONS AND METHODS FOR DETECTING GENE FUSIONS OF ESR1 AND CCDC170 FOR DETERMINING INCREASED RESISTANCE TO ENDOCRINE THERAPY AND FOR CANCER TREATMENT
#11PHARMACEUTICAL COMPOSITION FOR LOWERING BLOOD CHOLESTEROL, PREVENTING OR TREATING CARDIOVASCULAR DISEASES AND REDUCING INFLAMMATION
#12Compositions targeting the interaction domain between p27KIP1 and Brk and methods of use thereof to inhibit p27 Y phosphorylation and cdk4 activity
#13Cyclin G1 inhibitors and related methods of treating cancer
#14COMPOSITIONS AND METHODS OF USING ISLET NEOGENESIS PEPTIDES AND ANALOGS THEREOF
#15INHIBITORS OF CYCLIN-DEPENDENT KINASES
#16METHODS OF PROMOTING LONG-TERM SURVIVAL OF PATIENTS WITH ADVANCED CHEMOTHERAPY-RESISTANT MALIGNANCIES
#17CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS
#18Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#19Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#20Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#21SLIDING CLAMP-BASED AFFINITY PURIFICATION SYSTEMS, METHODS OF MAKING AND USE THEREOF
#22Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#23Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#24Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#25TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER
#26NOVEL ALK AND NTRK1 FUSION MOLECULES AND USES THEREOF
#27METHODS AND COMPOSITIONS TO INHIBIT METASTASIS AND TO TREAT FIBROSIS AND TO ENHANCE WOUND HEALING
#28Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#29INHIBITORS OF CYCLIN-DEPENDENT KINASES
#30MPS PEPTIDES AND USE THEREOF
#31Compositions and methods involving engineered p27
#32COMPOSITIONS AND METHODS OF USING ISLET NEOGENESIS PEPTIDES AND ANALOGS THEREOF
#33Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#34CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS
#35Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#36Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
#37Inhibitors of cyclin-dependent kinases
#38TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof
#39Method for regulating targeting of Cyclin Y (CCNY) protein to synapses
#40Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#41Peptidomimetic macrocycles and uses thereof
#42NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY HOMOLOGY-DIRECTED TRANSGENE INTEGRATION
#43CAPCNA PEPTIDE THERAPEUTICS FOR CANCER
#44Cyclin G1 inhibitors and related methods of treating cancer
#45HYBRID NUCLEIC ACID MOLECULES AND THEIR USE
#46Compositions targeting the interaction domain between p27Kip1 and Brk and methods of use thereof to inhibit p27 Y phosphorylation and cdk4 activity
#47Reducing abnormal accumulation of TDP-43 in motor neurons in amyotrophic lateral sclerosis and/or frontotemporal dementia using a construct encoding cyclin F
#48Fusion proteins and methods thereof
#49Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#50CYCLIN A1-TARGETED T-CELL IMMUNOTHERAPY FOR CANCER
#51Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#52Conditionally immortalized long-term stem cells and methods of making and using such cells
#53Compositions and methods of using islet neogenesis peptides and analogs thereof
#54Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
#55ALK and NTRK1 fusion molecules and uses thereof
#56Methods and compositions relating to chimeric antigen receptors
#57Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#58TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof
#59Inhibitors of cyclin-dependent kinases
#60Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#61Anti-bacterial agents and their use in therapy
#62Immunogenic peptides of the cyclin B1 tumor antigen
#63CDCA1-derived peptide and vaccine containing same
#64NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS
#65Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
#66COMPOSITIONS AND METHODS OF USING ISLET NEOGENESIS PEPTIDES AND ANALOGS THEREOF
#67HLA-DR binding peptides and their uses
#68Oligopeptidic compounds and uses thereof
#69Nucleic acid sequence encoding a fusion protein
#70Method of expressing a G-protein coupled receptor protein
#71CAPCNA peptide therapeutics for cancer
#72Compositions targeting the interaction domain between p27KiP1 and Brk and methods of use thereof to inhibit p27 Y phosphorylation and cdk4 activity
#73Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#74Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#75Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#76Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
#77Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#78Method for treating cancer with an activated T lymphocyte that selectively recognizes a cancer cell consisting of specific peptide
#79Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#80Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#81Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#82Compositions and methods of using islet neogenesis peptides and analogs thereof
#83RESTRICTING NUCLEAR PROTEIN TO SPECIFIC PHASES OF THE CELL CYCLE
#84Modulation of cellular localization of cyclin C
#85RECURRENT FUSION GENES IDENTIFIED IN HIGH -GRADE SEROUS OVARIAN CARCINOMA
#86IMMUNOGENIC PEPTIDES OF THE CYCLIN B1 TUMOR ANTIGEN
#87Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
#88TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof
#89MPS peptides and use thereof
#90Fusion proteins and methods thereof
#91Conjugate comprising P21 protein for the treatment of cancer
#92Conditionally immortalized long-term stem cells and methods of making and using such cells
#93P15 protein variant and use thereof for preventing or treating cancer
#94p16 protein variant and use thereof for preventing or treating cancer
#95Compositions and methods of using islet neogenesis peptides and analogs thereof
#96Method for detecting cancer via measurement of caprin-1 expression level
#97Methods And Marker Combinations For Screening For Predisposition To Lung Cancer
#98Fusion expression of G-protein coupled receptor
#99Oligopeptidic compounds and uses thereof
#100Cyclin based inhibitors of CDK2 and CDK4
#101ALK and NTRK1 fusion molecules and uses thereof
#102Cyclin A1-targeted T-cell immunotherapy for cancer
#103Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
#104Peptide based inhibition of caPCNA interaction in cancer
#105Method for therapeutic angiogenesis
#106Protein complex comprising MCM8 and MCM9 proteins and their use
#107CAPCNA peptide therapeutics for cancer
#108Method for detecting pancreatic cancer
#109MPHOSPH1 peptides and vaccines including the same
#110HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide
#111Polynucleotides comprising a reporter sequence operatively linked to a regulatory element
#112Use of a new gene coding for a new member of the MCM2-8 family in pharmaceutical compositions
#113Methods and vectors for cell immortalisation
#114Methods and compositions inhibiting tumor cell proliferation
#115Cancer therapy based on tumor associated antigens derived from cyclin D1
#116Survivin-derived peptides and uses thereof
#117CELL GROWTH INHIBITOR DERIVED FROM p16INK4a AND METHOD OF SYNTHESIZING THE SAME
#118COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND NEUTROPENIA
#119CAPCNA PEPTIDE THERAPEUTICS FOR CANCER
#120Nucleic acid expression construct and its use as a cell proliferation marker
#121Therapeutic approach to neurodegenerative disorders using a TFP5-peptide
#122Method for therapeutic angiogenesis
#123Methods And Marker Combinations For Screening For Predisposition To Lung Cancer
#124Cancer therapy based on tumor associated antigens derived from cyclin D1
#125MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
#126VECTOR(S) CONTAINING AN INDUCIBLE GENE ENCODING A CDK4/CDK6 INHIBITOR USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS OR DISEASES ASSOCIATED WITH AN UNSCHEDULED ACTIVATION OF THE CELL CYCLE
#127TetO-p16 transgenic mice
#128Polypeptides derived from cyclin B1 and uses thereof
#129E2EPF Ubiquitin Carrier Protein-Von Hippel-Lindau Interaction and Uses Thereof
#130csPCNA Isoform Modifications And Uses Thereof
#131Compositions and methods of using proislet peptides and analogs thereof
#132Cytotoxic T-Lymphocyte-Inducing Immunogens for Prevention, Treatment and Diagnosis of Cancer
#133MCT-1, A HUMAN ONCOGENE
#134CALMODULIN-BINDING PEPTIDES THAT REDUCE CELL PROLIFERATION IN CANCER AND SMOOTH MUSCLE PROLIFERATION DISEASES
#135METHODS AND COMPOSITIONS FOR CELL-CYCLE REGULATION
#136COMPOSITIONS AND METHODS FOR MEDIATING CELL CYCLE PROGRESSION
#137USE OF P27KIP1 FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
#138Cell proliferation reducing cancer specific PCNA peptides
#139Use of a new gene coding for a new member of the MCM2-8 family in pharmaceutical compositions
#140Conjugate comprising P21 protein for the treatment of cancer
#141Oligopeptidic compounds and uses thereof
#142PROLIFERATION MARKERS IN CLINICAL PRACTICE AND THEIR USE FOR BREAST CANCER PROGNOSIS OR DIAGNOSIS
#143HLA-DR BINDING PEPTIDES AND THEIR USES
#144Conditionally immortalized long-term stem cells and methods of making and using such cells
#145Anticancer vaccine and diagnostic methods and reagents
#146METHOD FOR PURIFYING CANCER-SPECIFIC PROLIFERATING CELL NUCLEAR ANTIGEN
#147METHOD FOR THE SCREENING PROTEASOME OF ACTIVITY-MODULATING AGENTS AND MEANS FOR CARRYIING OUT SAID METHOD
#148Compounds for enhancing p21 expression and methods of use thereof
#149Inhibiting cyclin D polypeptides
#150Detection of cellular stress
#151cDNA Encoding a Gene Bog (B5T Over-Expressed Gene) and its Protein Product
#152Cell Cycle Genes and Related Methods
#153Protein-Protein Interaction Biosensors and Methods of Use Thereof
#154Substrates of N-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrate
#155Cell cycle phase markers
#156Monoclonal antibodies and methods for their use in the detection of cervical disease
#157Peptide based inhibition of caPCNA interaction in cancer
#158Mutant PCNA
#159Methods and compositions for increasing protein yield from a cell culture
#160csPCNA isoform modifications and uses thereof
#161Transgenic non-human animal model of lung tumorigenesis
#162MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
#163Parkin interacting polypeptides and methods of use
#164Conjugate Comprising P21 Protein for the Treatment of Cancer
#165Dna Replication Modulating Peptides, Nucleic Acids Encoding Them, and Their Use in Pharmaceutical Compositions
#166E2epf Ubiquitin Carrier Protein-Von Hippel-Lindau Interaction and Uses Thereof
#167Animal models of pancreatic adenocarcinoma and uses therefor
#168Method for purifying cancer-specific proliferating cell nuclear antigen
#169METHODS OF SYNTHESIZING AND PRESERVING A NUCLEOTIDE-LABELED MICROTUBULE
#170Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
#171CELL REGULATORY GENES, ENCODED PRODUCTS, AND USES RELATED THERETO
#172Crystal Structure of Human Proliferating Cell Nuclear Antigen (Pcna) and Uses Thereof
#173Methods and marker combinations for screening for predisposition to lung cancer
#174Methods and compositions for cell-cycle regulation
#175Tyrosine Phosphorylation of Cdk Inhibitor Proteins of the Cip/Kip Family
#176Cell cycle progressional proteins
#177Cell cycle phase markers
#178Methods of identifying an agent capable of interfering with Rad9 dephosphorylation
#179METHOD FOR DETERMINING CELL CYCLE POSITION
#180Human and murine Mus81 proteins
#181CELL CYCLE MARKERS
#182MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
#183Expression of cyclin G1 in tumors
#184Parkin interacting polypeptides and methods of use
#185Survivin-derived peptides and use thereof
#186Plants having improved yield and method for making the same
#187Monoclonal antibodies and methods for their use in the detection of cervical disease
#188Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
#189Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
#190Use of eukaryotic genes affecting spindle formation or microtubule function during cell division for diagnosis and treatment of proliferative diseases
#191Proliferation markers in clinical practice and their use for cancer prognosis or diagnosis
#192Genes and proteins encoded thereby
#193Triazolopyrimidine derivatives
#194Use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferative diseases
#195Method of growing myocardial cells
#196Cyclin groove inhibitors
#197Monoclonal antibodies and methods for their use in the detection of cervical disease
#198Novel RIP3 associated cell cycle proteins, compositions and methods of use
#199Cell-cycle checkpoint genes
#200Anticancer vaccine and diagnostic methods and reagents
#201Animal model for the fast identification of pharmaceutical active compounds in vivo
#202Activators of cyclin-dependent kinases
#203Cell regulatory genes, encoded products, and uses related thereto
#204Modifications of plant traits using cyclin A
#205Antibodies to cyclin E2 protein
#206Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof
#207CDK2/cyclin A crystals and uses thereof
#208Regulation of the P21 gene and uses thereof
#209Cell cycle progression proteins
#210Compositions and methods for increasing animal size growth rate
#211Screen for CDC7 inhibitors
#212Methods for proliferating cardiomyocytes and recombinant vectors therefor
#213hKIS composition and methods of use
#214Novel cell cycle genes required for mitotic entry
#215Expression vectors for increasing protein yield from a cell culture and methods of use thereof
#216Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents
#217Human diaphanous-3 gene and methods of use therefor
#218Methods for identifying and using maintenance genes
#219Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor
#220Human cyclin I and genes encoding same